$2.91
0.055[1.93%]
At close: Apr 26
$2.91
0[0.00%]
After Hours: 5:03PM EDT
Allogene Therapeutics
(NASDAQ:ALLO)Allogene Therapeutics Stock (NASDAQ:ALLO), Analyst Ratings, Price Targets, Predictions
Allogene Therapeutics Inc has a consensus price target of $15.72, established from looking at the 57 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., RBC Capital, and JP Morgan on March 19, 2024, March 15, 2024, and February 27, 2024. With an average price target of $9.33 between HC Wainwright & Co., RBC Capital, and JP Morgan, there's an implied 220.73% upside for Allogene Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
RBC Capital
JP Morgan
Guggenheim
JMP Securities
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Allogene Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/19/2024 | ALLO | Buy Now | Allogene Therapeutics | $2.91 | 243.64% | HC Wainwright & Co. | Robert Burns | → $10 | Reiterates | Buy → Buy | Get Alert |
| 03/15/2024 | ALLO | Buy Now | Allogene Therapeutics | $2.91 | 243.64% | RBC Capital | Luca Issi | → $10 | Reiterates | Outperform → Outperform | Get Alert |
| 02/27/2024 | ALLO | Buy Now | Allogene Therapeutics | $2.91 | 174.91% | JP Morgan | Brian Cheng | $9 → $8 | Maintains | Overweight | Get Alert |
| 01/19/2024 | ALLO | Buy Now | Allogene Therapeutics | $2.91 | 243.64% | HC Wainwright & Co. | Robert Burns | $12 → $10 | Maintains | Buy | Get Alert |
| 01/05/2024 | ALLO | Buy Now | Allogene Therapeutics | $2.91 | — | Guggenheim | Michael Schmidt | — | Downgrade | Buy → Neutral | Get Alert |
| 01/05/2024 | ALLO | Buy Now | Allogene Therapeutics | $2.91 | — | JMP Securities | Reni Benjamin | — | Downgrade | Market Outperform → Market Perform | Get Alert |
| 12/08/2023 | ALLO | Buy Now | Allogene Therapeutics | $2.91 | 140.55% | Citigroup | Samantha Semenkow | → $7 | Initiates | → Buy | Get Alert |
| 11/15/2023 | ALLO | Buy Now | Allogene Therapeutics | $2.91 | 312.37% | HC Wainwright & Co. | Robert Burns | $23 → $12 | Maintains | Buy | Get Alert |
| 09/25/2023 | ALLO | Buy Now | Allogene Therapeutics | $2.91 | 209.28% | JP Morgan | Brian Cheng | $11 → $9 | Maintains | Overweight | Get Alert |
| 08/07/2023 | ALLO | Buy Now | Allogene Therapeutics | $2.91 | 690.38% | HC Wainwright & Co. | Robert Burns | → $23 | Reiterates | Buy → Buy | Get Alert |
| 08/03/2023 | ALLO | Buy Now | Allogene Therapeutics | $2.91 | 862.2% | Oppenheimer | Mark Breidenbach | → $28 | Reiterates | Outperform → Outperform | Get Alert |
| 08/03/2023 | ALLO | Buy Now | Allogene Therapeutics | $2.91 | 415.46% | EF Hutton | Tony Butler | → $15 | Reiterates | Buy → Buy | Get Alert |
| 07/12/2023 | ALLO | Buy Now | Allogene Therapeutics | $2.91 | 518.56% | Truist Securities | Asthika Goonewardene | $20 → $18 | Maintains | Buy | Get Alert |
| 06/26/2023 | ALLO | Buy Now | Allogene Therapeutics | $2.91 | 862.2% | Oppenheimer | Mark Breidenbach | → $28 | Assumes | → Outperform | Get Alert |
| 06/20/2023 | ALLO | Buy Now | Allogene Therapeutics | $2.91 | 690.38% | HC Wainwright & Co. | Robert Burns | → $23 | Reiterates | Buy → Buy | Get Alert |
| 06/16/2023 | ALLO | Buy Now | Allogene Therapeutics | $2.91 | 1102.75% | Canaccord Genuity | John Newman | → $35 | Reiterates | Buy → Buy | Get Alert |
| 06/05/2023 | ALLO | Buy Now | Allogene Therapeutics | $2.91 | 415.46% | JMP Securities | Reni Benjamin | → $15 | Reiterates | → Market Outperform | Get Alert |
| 06/05/2023 | ALLO | Buy Now | Allogene Therapeutics | $2.91 | 415.46% | EF Hutton | Tony Butler | → $15 | Reiterates | Buy → Buy | Get Alert |
| 05/26/2023 | ALLO | Buy Now | Allogene Therapeutics | $2.91 | 415.46% | EF Hutton | Tony Butler | → $15 | Reiterates | Buy → Buy | Get Alert |
FAQ
What is the target price for Allogene Therapeutics (ALLO)?
The latest price target for Allogene Therapeutics (NASDAQ: ALLO) was reported by HC Wainwright & Co. on March 19, 2024. The analyst firm set a price target for $10.00 expecting ALLO to rise to within 12 months (a possible 243.64% upside). 23 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Allogene Therapeutics (ALLO)?
The latest analyst rating for Allogene Therapeutics (NASDAQ: ALLO) was provided by HC Wainwright & Co., and Allogene Therapeutics reiterated their buy rating.
When was the last upgrade for Allogene Therapeutics (ALLO)?
The last upgrade for Allogene Therapeutics Inc happened on January 24, 2023 when JP Morgan raised their price target to $11. JP Morgan previously had a neutral for Allogene Therapeutics Inc.
When was the last downgrade for Allogene Therapeutics (ALLO)?
The last downgrade for Allogene Therapeutics Inc happened on January 5, 2024 when Guggenheim changed their price target from N/A to N/A for Allogene Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Allogene Therapeutics (ALLO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Allogene Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Allogene Therapeutics was filed on March 19, 2024 so you should expect the next rating to be made available sometime around March 19, 2025.
Is the Analyst Rating Allogene Therapeutics (ALLO) correct?
While ratings are subjective and will change, the latest Allogene Therapeutics (ALLO) rating was a reiterated with a price target of $0.00 to $10.00. The current price Allogene Therapeutics (ALLO) is trading at is $2.91, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.